top of page

Recent News


Nanomerics Reports Last Volunteer Visit in the OC134 Sunlight Trial; The Sunlight Trial Met Its Primary Endpoints
LONDON, UK / ACCESS Newswire / March 10, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had...
Mar 10


Nanomerics reports complete dosing of the last volunteer in the OC134 SUNLIGHT trial
Nanomerics today announced end of dosing with all volunteers completing the full schedule and without moderate or severe adverse events...
Jan 9


Nanomerics’ CSO made a Dame Commander in the UK New Year’s 2025 Honours
Nanomerics Ltd., a private speciality pharmaceutical company today announced that its Chief Scientific Officer, Professor Ijeoma F....
Jan 9


Dosing has commenced in the SUNLIGHT trial (OC134 Phase I)
Following approval in November 2024 from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), dosing of the first...
Dec 13, 2024


MHRA grants Nanomerics clinical trials authorisation notice for its upcoming OC134 clinical trial
London, United Kingdom, November 18th, 2024. Nanomerics Ltd ., a private speciality pharmaceutical company announced that it had...
Nov 18, 2024


Nanomerics CSO Ijeoma Uchegbu's "Life Scientific" BBC Radio 4 Program
Nanomerics CSO Prof IF Uchegbu chats to Jim Al-Khalili about her life - scientific and otherwise. The program is available on BBC Sounds...
Sep 3, 2024


Nanomerics Hosts Successful Industry Site Visit for RSC Broadening Horizons Participants
In collaboration with the Royal Society of Chemistry (RSC), Nanomerics recently hosted an industry site visit for the participants of the...
Sep 2, 2024


Nanomerics Supports the RSC Broadening Horizons in the Chemical Sciences Programme for the third year
Nanomerics proudly announces its continuous participation as an industry partner in the Royal Society of Chemistry's (RSC) Broadening...
Sep 2, 2024


Nanomerics CSO delivers keynote lecture at the Business of Science 2024 Conference
Manchester, United Kingdom May 22nd, 2024. Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor...
May 23, 2024


Nanomerics wins the United Kingdom King’s Award for Enterprise 2024
London, United Kingdom May 6th, 2024. Nanomerics Ltd ., a private speciality pharmaceutical company today announced that it had been...
May 6, 2024


Nanomerics CSO delivers the 2024 Annual Anne McLaren lecture
London, United Kingdom April 24th 2024. Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor...
May 6, 2024


Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada
Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in...
Apr 13, 2023


Anti-COVID19 prophylactic paper published in October 2021 already downloaded over 3600 times
Today Nanomerics is pleased to announce that the publication (SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may...
Jan 4, 2023


Wellcome Board Appointment
Nanomerics CSO Ijeoma Uchegbu has been appointed to the board of Wellcome Ijeoma Uchegbu appointed to Wellcome board | News | Wellcome
Nov 11, 2021


Nanomerics announces ocular progress with new patents and two key publications
Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced the Company had been granted patent...
May 23, 2021


Nanomerics CSO Prof IF Uchegbu elected to Academy of Medical Sciences
Today the UK Academy of Medical Sciences announced the election of 50 new biomedical health scientists to its influential fellowship;...
May 12, 2021


Double Milestone Payment Strengthens Nanomerics' Balance Sheet and Enables Clinical Programs
Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first...
Mar 23, 2021


Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication
Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication in ex-vivo human airway epithelial air liquid interface cultures. Today...
Dec 12, 2020


Nanomerics receives pIND guidance from the US FDA for NM134
Today Nanomerics received supportive pIND guidance from the US FDA on the development of its asset - NM134. NM134 is indicated for the...
Aug 3, 2020
bottom of page